These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19126297)

  • 21. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K; Yasuda N; Inoue T; Nagakura T; Kira K; Shinoda M; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1253-7. PubMed ID: 16980568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
    Tiwari A
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biological evaluation of novel benzyl-substituted (S)-phenylalanine derivatives as potent dipeptidyl peptidase 4 inhibitors.
    Liu Y; Si M; Tang L; Shangguan S; Wu H; Li J; Wu P; Ma X; Liu T; Hu Y
    Bioorg Med Chem; 2013 Sep; 21(18):5679-87. PubMed ID: 23938053
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
    Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
    Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors.
    Ikuma Y; Hochigai H; Kimura H; Nunami N; Kobayashi T; Uchiyama K; Furuta Y; Sakai M; Horiguchi M; Masui Y; Okazaki K; Sato Y; Nakahira H
    Bioorg Med Chem; 2012 Oct; 20(19):5864-83. PubMed ID: 22938786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highly potent dipeptidyl peptidase IV inhibitors derived from Alogliptin through pharmacophore hybridization and lead optimization.
    Xie H; Zeng L; Zeng S; Lu X; Zhao X; Zhang G; Tu Z; Xu H; Yang L; Zhang X; Wang S; Hu W
    Eur J Med Chem; 2013 Oct; 68():312-20. PubMed ID: 23994324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase-4 inhibitor with β-amino amide scaffold: synthesis, SAR and biological evaluation.
    Kim HJ; Kwak WY; Min JP; Sung SY; Kim HD; Kim MK; Kim HS; Park KJ; Son MH; Kim SH; Lee BJ
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5545-9. PubMed ID: 22850208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.
    Fukuda-Tsuru S; Anabuki J; Abe Y; Yoshida K; Ishii S
    Eur J Pharmacol; 2012 Dec; 696(1-3):194-202. PubMed ID: 23022337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
    Eckhardt M; Langkopf E; Mark M; Tadayyon M; Thomas L; Nar H; Pfrengle W; Guth B; Lotz R; Sieger P; Fuchs H; Himmelsbach F
    J Med Chem; 2007 Dec; 50(26):6450-3. PubMed ID: 18052023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and preclinical profile of teneligliptin (3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl)piperazin-1-yl]pyrrolidin-2-ylcarbonyl]thiazolidine): a highly potent, selective, long-lasting and orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Yoshida T; Akahoshi F; Sakashita H; Kitajima H; Nakamura M; Sonda S; Takeuchi M; Tanaka Y; Ueda N; Sekiguchi S; Ishige T; Shima K; Nabeno M; Abe Y; Anabuki J; Soejima A; Yoshida K; Takashina Y; Ishii S; Kiuchi S; Fukuda S; Tsutsumiuchi R; Kosaka K; Murozono T; Nakamaru Y; Utsumi H; Masutomi N; Kishida H; Miyaguchi I; Hayashi Y
    Bioorg Med Chem; 2012 Oct; 20(19):5705-19. PubMed ID: 22959556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hibiscus sabdariffa polyphenols alleviate insulin resistance and renal epithelial to mesenchymal transition: a novel action mechanism mediated by type 4 dipeptidyl peptidase.
    Peng CH; Yang YS; Chan KC; Wang CJ; Chen ML; Huang CN
    J Agric Food Chem; 2014 Oct; 62(40):9736-43. PubMed ID: 25226384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel series of 3-amino-N-(4-aryl-1,1-dioxothian-4-yl)butanamides as potent and selective dipeptidyl peptidase IV inhibitors.
    Nitta A; Fujii H; Sakami S; Satoh M; Nakaki J; Satoh S; Kumagai H; Kawai H
    Bioorg Med Chem Lett; 2012 Dec; 22(23):7036-40. PubMed ID: 23072865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and potent inhibitory activities of carboxybenzyl-substituted 8-(3-(R)-aminopiperidin-1-yl)-7-(2-chloro/cyanobenzyl)-3-methyl-3,7-dihydro-purine-2,6-diones as dipeptidyl peptidase IV (DPP-IV) inhibitors.
    Mo DW; Dong S; Sun H; Chen JS; Pang JX; Xi BM; Chen WH
    Bioorg Med Chem Lett; 2015 May; 25(9):1872-5. PubMed ID: 25838146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of potent dipeptidyl peptidase IV inhibitors through pharmacophore hybridization and hit-to-lead optimization.
    Zeng S; Xie H; Zeng LL; Lu X; Zhao X; Zhang GC; Tu ZC; Xu HJ; Yang L; Zhang XQ; Hu W
    Bioorg Med Chem; 2013 Apr; 21(7):1749-55. PubMed ID: 23434133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of DPP-4 inhibition on cardiac metabolism and function in mice.
    Lenski M; Kazakov A; Marx N; Böhm M; Laufs U
    J Mol Cell Cardiol; 2011 Dec; 51(6):906-18. PubMed ID: 21871459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, Synthesis and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel DPP-4 Inhibitors.
    Li Q; Zhou M; Han L; Cao Q; Wang X; Zhao L; Zhou J; Zhang H
    Chem Biol Drug Des; 2015 Oct; 86(4):849-56. PubMed ID: 25787859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics and pharmacodynamics of linagliptin.
    Graefe-Mody U; Retlich S; Friedrich C
    Clin Pharmacokinet; 2012 Jul; 51(7):411-27. PubMed ID: 22568694
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
    Deng X; Han L; Zhou J; Zhang H; Li Q
    Bioorg Chem; 2017 Dec; 75():357-367. PubMed ID: 29096096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
    Uchii M; Sakai M; Hotta Y; Saeki S; Kimoto N; Hamaguchi A; Kitayama T; Kunori S
    J Pharmacol Sci; 2017 Nov; 135(3):126-130. PubMed ID: 29113790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.